2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Thoracic
2
Other hematologic neoplasm
2
Sarcoma
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Wilms Tumor
1
Testicular Neoplasms
1
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Neutrophilic, Chronic
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Hodgkin Disease
1
Dendritic Cell Sarcoma, Interdigitating
1
Congenital Abnormalities
1
Interventions
Dexamethasone
881
Bortezomib
478
Lenalidomide
467
Cyclophosphamide
367
Melphalan
275
Calcium Dobesilate
264
daratumumab
240
pomalidomide
215
carfilzomib
188
fludarabine phosphate
141
fludarabine
137
Thalidomide
125
Peripheral Blood Stem Cell Transplantation
120
Filgrastim
115
ixazomib
94
Mycophenolic Acid
91
Granulocyte Colony-Stimulating Factor
90
Busulfan
89
Whole-Body Irradiation
88
dexamethasone acetate
87
Tacrolimus
79
dexamethasone 21-phosphate
74
isatuximab
68
Cyclosporine
68
auricularum
67
Prednisone
67
elotuzumab
63
belantamab mafodotin
59
Antilymphocyte Serum
56
Etoposide
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lithium
×
Plasma cell
×
Clear all
NCT00408681
2017-03-07
GVHD
Fred Hutchinson Cancer Center
Phase NA
Completed
20 enrolled
27 charts